Priority Health announced it plans to cover the FoundationOne and FoundationOne Heme genomic profiles for patients with cancer developed by Foundation Medicine Inc.
The Centers for Medicare and Medicaid Services published two draft local coverage determinations for prostate cancer tests. The drafts were issued through Medicare contractor Palmetto GBA's MolDx Program.
Cancer Support Community released the findings report from the first year-and-a-half of the Cancer Experience Registry.
The Health Resources and Services Administration last week warned pharmaceutical companies that they must continue to offer 340B Drug Pricing Program discounts on some uses of orphan drugs.
Caris Life Sciences Inc. last week reduced its workforce by 50 people—about 20 percent, sources said.
The Cancer Letter asked Lawrence Einhorn, distinguished professor of medicine and the Livestrong Foundation Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center, to reflect on one of the most spectacular successes in the history of cancer research—his development of the curative regimen for testicular cancer.
On Oct. 21, 1974, John Cleland lay in a hospital bed at Indiana University Hospital.
Stand Up To Cancer Canada will support two, four-year cancer research dream teams with nearly $20 million USD raised by SU2C Canada collaborators and from the charity's September telecast. The dream teams will focus their research on translational research in breast cancer and cancer stem cells.
FDA approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma.
FDA granted priority review to the investigational bispecific T-cell engager antibody construct blinatumomab for the treatment of adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.\
